| Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein C Balducci, M Beeg, M Stravalaci, A Bastone, A Sclip, E Biasini, L Tapella, ... Proceedings of the National Academy of Sciences 107 (5), 2295-2300, 2010 | 552 | 2010 |
| A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis G Di Fede, M Catania, M Morbin, G Rossi, S Suardi, G Mazzoleni, ... Science 323 (5920), 1473-1477, 2009 | 452 | 2009 |
| Regulation of leukocyte recruitment by the long pentraxin PTX3 L Deban, RC Russo, M Sironi, F Moalli, M Scanziani, V Zambelli, ... Nature immunology 11 (4), 328-334, 2010 | 451 | 2010 |
| Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. S Sozzani, W Luini, A Borsatti, N Polentarutti, D Zhou, L Piemonti, ... Journal of immunology (Baltimore, Md.: 1950) 159 (4), 1993-2000, 1997 | 446 | 1997 |
| Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis M Morigi, M Galbusera, S Gastoldi, M Locatelli, S Buelli, A Pezzotta, ... The Journal of Immunology 187 (1), 172-180, 2011 | 265 | 2011 |
| Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1 E Fumagalli, M Funicello, T Rauen, M Gobbi, T Mennini European journal of pharmacology 578 (2-3), 171-176, 2008 | 251 | 2008 |
| Cutting edge: scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6 AM Fra, M Locati, K Otero, M Sironi, P Signorelli, ML Massardi, M Gobbi, ... The Journal of Immunology 170 (5), 2279-2282, 2003 | 251 | 2003 |
| Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide S Mourtas, M Canovi, C Zona, D Aurilia, A Niarakis, B La Ferla, ... Biomaterials 32 (6), 1635-1645, 2011 | 234 | 2011 |
| Carrier‐dependent and Ca2+‐dependent 5‐HT and dopamine release induced by (+)‐amphetamine, 3, 4‐methylendioxy‐methamphetamine, p‐chloroamphetamine and (+)‐fenfluramine D Crespi, T Mennini, M Gobbi British journal of pharmacology 121 (8), 1735-1743, 1997 | 230 | 1997 |
| Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study L Obici, A Cortese, A Lozza, J Lucchetti, M Gobbi, G Palladini, S Perlini, ... Amyloid 19 (sup1), 34-36, 2012 | 220 | 2012 |
| The antidepressant mechanism of Hypericum perforatum T Mennini, M Gobbi Life sciences 75 (9), 1021-1027, 2004 | 218 | 2004 |
| An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo BR Fluharty, E Biasini, M Stravalaci, A Sclip, L Diomede, C Balducci, ... Journal of Biological Chemistry 288 (11), 7857-7866, 2013 | 206 | 2013 |
| Lipid-based nanoparticles with high binding affinity for amyloid-β1–42 peptide M Gobbi, F Re, M Canovi, M Beeg, M Gregori, S Sesana, S Sonnino, ... Biomaterials 31 (25), 6519-6529, 2010 | 197 | 2010 |
| Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy F Noè, AH Pool, J Nissinen, M Gobbi, R Bland, M Rizzi, C Balducci, ... Brain 131 (6), 1506-1515, 2008 | 179 | 2008 |
| Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial S Haïk, G Marcon, A Mallet, M Tettamanti, A Welaratne, G Giaccone, ... The Lancet Neurology 13 (2), 150-158, 2014 | 177 | 2014 |
| PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer’s disease D Brambilla, R Verpillot, B Le Droumaguet, J Nicolas, M Taverna, ... ACS nano 6 (7), 5897-5908, 2012 | 169 | 2012 |
| Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor R Bonecchi, M Locati, E Galliera, M Vulcano, M Sironi, AM Fra, M Gobbi, ... The Journal of Immunology 172 (8), 4972-4976, 2004 | 162 | 2004 |
| Development of a proteolytically stable retro-inverso peptide inhibitor of β-amyloid oligomerization as a potential novel treatment for Alzheimer’s disease M Taylor, S Moore, J Mayes, E Parkin, M Beeg, M Canovi, M Gobbi, ... Biochemistry 49 (15), 3261-3272, 2010 | 161 | 2010 |
| Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer’s disease B Le Droumaguet, J Nicolas, D Brambilla, S Mura, A Maksimenko, ... ACS nano 6 (7), 5866-5879, 2012 | 145 | 2012 |
| Recombinant C1 inhibitor in brain ischemic injury R Gesuete, C Storini, A Fantin, M Stravalaci, ER Zanier, F Orsini, ... Annals of Neurology: Official Journal of the American Neurological …, 2009 | 143 | 2009 |
Mario SalmonaCapo del Dipartimento di Biochimica e Farmacologia MolecolareVerified email at marionegri.it
